Chronic migraine: risk factors, mechanisms and treatment

Subjects

Key Points

  • Chronic migraine is a clearly defined subtype of migraine affecting between 1–2% of the general population, yet it receives little attention

  • Chronic migraine usually develops from episodic migraine at a conversion rate of about 3% a year; the chronification is reversible

  • Risk factors for migraine chronification include overuse of acute migraine medication, ineffective acute treatment, obesity, depression, low educational status and stressful life events

  • The pathophysiology of migraine chronification can be understood as a threshold problem: certain predisposing factors combined with frequent headache pain lower the threshold of migraine attacks, thereby increasing the risk of chronic migraine

  • Treatment options include pharmacological and nonpharmacological options and neuromodulation

  • Prevention of chronification is essential, and requires adequate treatment of individual migraine attacks, early initiation of preventive medication and avoiding analgesic overuse

Abstract

Chronic migraine has a great detrimental influence on a patient's life, with a severe impact on socioeconomic functioning and quality of life. Chronic migraine affects 1–2% of the general population, and about 8% of patients with migraine; it usually develops from episodic migraine at an annual conversion rate of about 3%. The chronification is reversible: about 26% of patients with chronic migraine go into remission within 2 years of chronification. The most important modifiable risk factors for chronic migraine include overuse of acute migraine medication, ineffective acute treatment, obesity, depression and stressful life events. Moreover, age, female sex and low educational status increase the risk of chronic migraine. The pathophysiology of migraine chronification can be understood as a threshold problem: certain predisposing factors, combined with frequent headache pain, lower the threshold of migraine attacks, thereby increasing the risk of chronic migraine. Treatment options include oral medications, nerve blockade with local anaesthetics or corticoids, and neuromodulation. Well-defined diagnostic criteria are crucial for the identification of chronic migraine. The International Headache Society classification of chronic migraine was recently updated, and now allows co-diagnosis of chronic migraine and medication overuse headache. This Review provides an up-to-date overview of the classification of chronic migraine, basic mechanisms and risk factors of migraine chronification, and the currently established treatment options.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Figure 1: Multiple factors contribute to migraine chronification.

References

  1. 1

    D'Amico, D. et al. Quality of life and disability in primary chronic daily headaches. Neurol. Sci. 24 (Suppl. 2), S97–S100 (2003).

    Google Scholar 

  2. 2

    Buse, D. C. et al. Chronic migraine prevalence, disability, and sociodemographic factors: results from the American Migraine Prevalence and Prevention Study. Headache 52, 1456–1470 (2012).

    Article  Google Scholar 

  3. 3

    Bigal, M. E., Serrano, D., Reed, M. & Lipton, R. B. Chronic migraine in the population: burden, diagnosis, and satisfaction with treatment. Neurology 71, 559–566 (2008).

    Article  Google Scholar 

  4. 4

    Katsarava, Z. et al. Primary headache disorders in the Republic of Georgia Prevalence and risk factors. Neurology 73, 1796–1803 (2009).

    CAS  Article  Google Scholar 

  5. 5

    Blumenfeld, A. M. et al. Disability, HRQoL and resource use among chronic and episodic migraineurs: results from the International Burden of Migraine Study (IBMS). Cephalalgia 31, 301–315 (2011).

    CAS  Article  Google Scholar 

  6. 6

    Wiendels, N. J. et al. Chronic frequent headache in the general population: comorbidity and quality of life. Cephalalgia 26, 1443–1450 (2006).

    CAS  Article  Google Scholar 

  7. 7

    Berra, E. et al. Cost of Chronic and Episodic Migraine. A pilot study from tertiary headache centre northern Italy. J. Headache Pain 16, 532 (2015).

    CAS  Article  Google Scholar 

  8. 8

    Munakata, J. et al. Economic burden of transformed migraine: results from the American Migraine Prevalence and Prevention (AMPP) Study. Headache 49, 498–508 (2009).

    Article  Google Scholar 

  9. 9

    iHeadache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia 33, 629–808 (2013).

  10. 10

    Headache Classification Committee et al. New appendix criteria open for a broader concept of chronic migraine. Cephalalgia 26, 742–746 (2006).

  11. 11

    Straube, A. et al. Prevalence of chronic migraine and medication overuse headache in Germany — the German DMKG headache study. Cephalalgia 30, 207–213 (2010).

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  12. 12

    Scher, A. I., Stewart, W. F., Liberman, J. & Lipton, R. B. Prevalence of frequent headache in a population sample. Headache 38, 497–506 (1998).

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  13. 13

    Yoon, M.-S. et al. Prevalence of primary headaches in Germany: results of the German Headache Consortium Study. J. Headache Pain 13, 215–223 (2012).

    Article  PubMed  PubMed Central  Google Scholar 

  14. 14

    Silberstein, S. D., Lipton, R. B. & Sliwinski, M. Classification of daily and near-daily headaches: field trial of revised IHS criteria. Neurology 47, 871–875 (1996).

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  15. 15

    Scher, A. I., Stewart, W. F., Ricci, J. A. & Lipton, R. B. Factors associated with the onset and remission of chronic daily headache in a population-based study. Pain 106, 81–89 (2003).

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  16. 16

    Mathew, N. T., Reuveni, U. & Perez, F. Transformed or evolutive migraine. Headache 27, 102–106 (1987).

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  17. 17

    Buse, D. C., Manack, A., Serrano, D., Turkel, C. & Lipton, R. B. Sociodemographic and comorbidity profiles of chronic migraine and episodic migraine sufferers. J. Neurol. Neurosurg. Psychiatry 81, 428–432 (2010).

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  18. 18

    Manack, A., Buse, D. C., Serrano, D., Turkel, C. C. & Lipton, R. B. Rates, predictors, and consequences of remission from chronic migraine to episodic migraine. Neurology 76, 711–718 (2011).

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  19. 19

    Mathew, N. T., Kurman, R. & Perez, F. Drug induced refractory headache — clinical features and management. Headache 30, 634–638 (1990).

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  20. 20

    Kudrow, L. Paradoxical effects of frequent analgesic use. Adv. Neurol. 33, 335–341 (1982).

    CAS  PubMed  PubMed Central  Google Scholar 

  21. 21

    Katsarava, Z. et al. Incidence and predictors for chronicity of headache in patients with episodic migraine. Neurology 62, 788–790 (2004).

    CAS  Article  Google Scholar 

  22. 22

    Bahra, A., Walsh, M., Menon, S. & Goadsby, P. J. Does chronic daily headache arise de novo in association with regular use of analgesics? Headache 43, 179–190 (2003).

    Article  PubMed  PubMed Central  Google Scholar 

  23. 23

    Paemeleire, K., Bahra, A., Evers, S., Matharu, M. S. & Goadsby, P. J. Medication-overuse headache in patients with cluster headache. Neurology 67, 109–113 (2006).

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  24. 24

    Williams, L., O'Connell, K. & Tubridy, N. Headaches in a rheumatology clinic: when one pain leads to another. Eur. J. Neurol. 15, 274–277 (2008).

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  25. 25

    Zwart, J.-A., Dyb, G., Hagen, K., Svebak, S. & Holmen, J. Analgesic use: a predictor of chronic pain and medication overuse headache: the Head-HUNT Study. Neurology 61, 160–164 (2003).

    Article  PubMed  PubMed Central  Google Scholar 

  26. 26

    Bigal, M. E. et al. Acute migraine medications and evolution from episodic to chronic migraine: a longitudinal population-based study. Headache 48, 1157–1168 (2008).

    Article  PubMed  PubMed Central  Google Scholar 

  27. 27

    Lipton, R. B. et al. Ineffective acute treatment of episodic migraine is associated with new-onset chronic migraine. Neurology 84, 688–695 (2015).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. 28

    Bigal, M. E., Liberman, J. N. & Lipton, R. B. Obesity and migraine: a population study. Neurology 66, 545–550 (2006).

    Article  PubMed  PubMed Central  Google Scholar 

  29. 29

    Bigal, M. E. & Lipton, R. B. Obesity is a risk factor for transformed migraine but not chronic tension-type headache. Neurology 67, 252–257 (2006).

    Article  PubMed  PubMed Central  Google Scholar 

  30. 30

    Ashina, S. et al. Depression and risk of transformation of episodic to chronic migraine. J. Headache Pain 13, 615–624 (2012).

    Article  PubMed  PubMed Central  Google Scholar 

  31. 31

    Fava, A. et al. Chronic migraine in women is associated with insulin resistance: a cross-sectional study. Eur. J. Neurol. 21, 267–272 (2014).

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  32. 32

    Peterlin, B. L., Rosso, A. L., Rapoport, A. M. & Scher, A. I. Obesity and migraine: the effect of age, gender and adipose tissue distribution. Headache 50, 52–62 (2010).

    Article  PubMed  PubMed Central  Google Scholar 

  33. 33

    He, Z. et al. Metabolic syndrome in female migraine patients is associated with medication overuse headache: a clinic-based study in China. Eur. J. Neurol. 22, 1228–1234 (2015).

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  34. 34

    Kitamura, E., Kanazawa, N. & Hamada, J. Hyperleptinemia increases the susceptibility of the cortex to generate cortical spreading depression. Cephalalgia 35, 327–334 (2015).

    Article  PubMed  PubMed Central  Google Scholar 

  35. 35

    De Simone, R. et al. Intracranial pressure in unresponsive chronic migraine. J. Neurol. 261, 1365–1373 (2014).

    Article  PubMed  PubMed Central  Google Scholar 

  36. 36

    Mathew, N. T., Ravishankar, K. & Sanin, L. C. Coexistence of migraine and idiopathic intracranial hypertension without papilledema. Neurology 46, 1226–1230 (1996).

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  37. 37

    Vieira, D. S. S. et al. Idiopathic intracranial hypertension with and without papilloedema in a consecutive series of patients with chronic migraine. Cephalalgia 28, 609–613 (2008).

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  38. 38

    De Simone, R. & Ranieri, A. The role of intracranial hypertension in the chronification of migraine. Neurol. Sci. 36 (Suppl. 1), 23–28 (2015).

    Article  PubMed  PubMed Central  Google Scholar 

  39. 39

    Stuginski-Barbosa, J., Macedo, H. R., Bigal, M. E. & Speciali, J. G. Signs of temporomandibular disorders in migraine patients: a prospective, controlled study. Clin. J. Pain 26, 418–421 (2010).

    Article  PubMed  PubMed Central  Google Scholar 

  40. 40

    Corchs, F. et al. Sensitivity to aversive stimulation, posttraumatic symptoms and migraines: what do they have in common? Med. Hypotheses 77, 534–535 (2011).

    Article  Google Scholar 

  41. 41

    Peterlin, B. L., Tietjen, G., Meng, S., Lidicker, J. & Bigal, M. Post-traumatic stress disorder in episodic and chronic migraine. Headache 48, 517–522 (2008).

    Article  Google Scholar 

  42. 42

    Luconi, R. et al. Prognostic significance of personality profiles in patients with chronic migraine. Headache 47, 1118–1124 (2007).

    Article  Google Scholar 

  43. 43

    Stankewitz, A., Aderjan, D., Eippert, F. & May, A. Trigeminal nociceptive transmission in migraineurs predicts migraine attacks. J. Neurosci. 31, 1937–1943 (2011).

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  44. 44

    Judit, A., Sándor, P. S. & Schoenen, J. Habituation of visual and intensity dependence of auditory evoked cortical potentials tends to normalize just before and during the migraine attack. Cephalalgia 20, 714–719 (2000).

    CAS  Article  Google Scholar 

  45. 45

    Stankewitz, A. & May, A. Cortical excitability and migraine. Cephalalgia 27, 1454–1456 (2007).

    CAS  Article  Google Scholar 

  46. 46

    Weiller, C. et al. Brain stem activation in spontaneous human migraine attacks. Nat. Med. 1, 658–660 (1995).

    CAS  Article  Google Scholar 

  47. 47

    Maniyar, F. H., Sprenger, T., Monteith, T., Schankin, C. & Goadsby, P. J. Brain activations in the premonitory phase of nitroglycerin-triggered migraine attacks. Brain J. Neurol. 137, 232–241 (2014).

    Article  Google Scholar 

  48. 48

    Cosentino, G. et al. Cyclical changes of cortical excitability and metaplasticity in migraine: evidence from a repetitive transcranial magnetic stimulation study. Pain 155, 1070–1078 (2014).

    Article  PubMed  PubMed Central  Google Scholar 

  49. 49

    Schulte, L. H., Jürgens, T. P. & May, A. Photo-, osmo- and phonophobia in the premonitory phase of migraine: mistaking symptoms for triggers? J. Headache Pain 16, 14 (2015).

    Article  PubMed  PubMed Central  Google Scholar 

  50. 50

    Dahlem, M. A. et al. Understanding migraine using dynamic network biomarkers. Cephalalgia 35, 627–630 (2015).

    Article  Google Scholar 

  51. 51

    Lipton, R. B. et al. Cutaneous allodynia in the migraine population. Ann. Neurol. 63, 148–158 (2008).

    Article  PubMed  PubMed Central  Google Scholar 

  52. 52

    Louter, M. A. et al. Cutaneous allodynia as a predictor of migraine chronification. Brain J. Neurol. 136, 3489–3496 (2013).

    Article  Google Scholar 

  53. 53

    Bigal, M. E. et al. Prevalence and characteristics of allodynia in headache sufferers: a population study. Neurology 70, 1525–1533 (2008).

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  54. 54

    Bigal, M. E. & Lipton, R. B. Clinical course in migraine: conceptualizing migraine transformation. Neurology 71, 848–855 (2008).

    Article  Google Scholar 

  55. 55

    Welch, K. M., Nagesh, V., Aurora, S. K. & Gelman, N. Periaqueductal gray matter dysfunction in migraine: cause or the burden of illness? Headache 41, 629–637 (2001).

    CAS  Article  Google Scholar 

  56. 56

    Gentile, G. et al. Lack of association between oxidative stress-related gene polymorphisms and chronic migraine in an Italian population. Expert Rev. Neurother. 15, 215–225 (2015).

    CAS  Article  Google Scholar 

  57. 57

    Schulte, L. H., Sprenger, C. & May, A. Physiological brainstem mechanisms of trigeminal nociception: an fMRI study at 3T. NeuroImage 124, 518–525 (2015).

    Article  Google Scholar 

  58. 58

    Youssef, A. M., Macefield, V. G. & Henderson, L. A. Pain inhibits pain; human brainstem mechanisms. NeuroImage 124 (Pt A), 54–62 (2016).

    CAS  Article  Google Scholar 

  59. 59

    Stankewitz, A., Voit, H. L., Bingel, U., Peschke, C. & May, A. A new trigemino-nociceptive stimulation model for event-related fMRI. Cephalalgia 30, 475–485 (2010).

    CAS  Article  Google Scholar 

  60. 60

    Denuelle, M., Fabre, N., Payoux, P., Chollet, F. & Geraud, G. Hypothalamic activation in spontaneous migraine attacks. Headache 47, 1418–1426 (2007).

    Google Scholar 

  61. 61

    Cernuda-Morollón, E. et al. Increased VIP levels in peripheral blood outside migraine attacks as a potential biomarker of cranial parasympathetic activation in chronic migraine. Cephalalgia 35, 310–316 (2015).

    Article  Google Scholar 

  62. 62

    Cernuda-Morollón, E. et al. Interictal increase of CGRP levels in peripheral blood as a biomarker for chronic migraine. Neurology 81, 1191–1196 (2013).

    Article  CAS  Google Scholar 

  63. 63

    Burstein, R. et al. Thalamic sensitization transforms localized pain into widespread allodynia. Ann. Neurol. 68, 81–91 (2010).

    Article  PubMed  PubMed Central  Google Scholar 

  64. 64

    Andreou, A. P. & Goadsby, P. J. Topiramate in the treatment of migraine: a kainate (glutamate) receptor antagonist within the trigeminothalamic pathway. Cephalalgia 31, 1343–1358 (2011).

    Article  Google Scholar 

  65. 65

    Andreou, A. P., Shields, K. G. & Goadsby, P. J. GABA and valproate modulate trigeminovascular nociceptive transmission in the thalamus. Neurobiol. Dis. 37, 314–323 (2010).

    CAS  Article  Google Scholar 

  66. 66

    Summ, O., Charbit, A. R., Andreou, A. P. & Goadsby, P. J. Modulation of nocioceptive transmission with calcitonin gene-related peptide receptor antagonists in the thalamus. Brain 133, 2540–2548 (2010).

    Article  Google Scholar 

  67. 67

    De Felice, M. et al. Triptan-induced latent sensitization: a possible basis for medication overuse headache. Ann. Neurol. 67, 325–337 (2010).

    CAS  PubMed  PubMed Central  Google Scholar 

  68. 68

    Green, A. L. et al. Increased susceptibility to cortical spreading depression in an animal model of medication-overuse headache. Cephalalgia 34, 594–604 (2014).

    Article  Google Scholar 

  69. 69

    Becerra, L. et al. Triptans disrupt brain networks and promote stress-induced CSD-like responses in cortical and subcortical areas. J. Neurophysiol. 115, 208–217 (2016).

    CAS  Article  Google Scholar 

  70. 70

    de Tommaso, M. et al. Central sensitisation phenomena in primary headaches: overview of a preventive therapeutic approach. CNS Neurol. Disord. Drug Targets 7, 524–535 (2008).

    CAS  Article  Google Scholar 

  71. 71

    Evers, S., Jensen, R. & European Federation of Neurological Societies. Treatment of medication overuse headache — guideline of the EFNS headache panel. Eur. J. Neurol. 18, 1115–1121 (2011).

    CAS  Article  Google Scholar 

  72. 72

    Rossi, P., Jensen, R., Nappi, G., Allena, M. & COMOESTAS Consortium. A narrative review on the management of medication overuse headache: the steep road from experience to evidence. J. Headache Pain 10, 407–417 (2009).

    Article  PubMed  PubMed Central  Google Scholar 

  73. 73

    Diener, H.-C. et al. Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study. Cephalalgia 27, 814–823 (2007).

    Article  Google Scholar 

  74. 74

    Aurora, S. K. et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia 30, 793–803 (2010).

    CAS  Article  Google Scholar 

  75. 75

    Diener, H. C. et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia 30, 804–814 (2010).

    CAS  Article  Google Scholar 

  76. 76

    Dodick, D. W. et al. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache 50, 921–936 (2010).

    Article  Google Scholar 

  77. 77

    Chiang, C.-C., Schwedt, T. J., Wang, S.-J. & Dodick, D. W. Treatment of medication-overuse headache: a systematic review. Cephalalgia 36, 371–386 (2016).

    Article  Google Scholar 

  78. 78

    Holroyd, K. A., Penzien, D. B. & Cordingley, G. E. Propranolol in the management of recurrent migraine: a meta-analytic review. Headache 31, 333–340 (1991).

    CAS  Article  Google Scholar 

  79. 79

    Linde, K. & Rossnagel, K. Propranolol for migraine prophylaxis. Cochrane Database Syst. Rev. 2, CD003225 (2004).

    Google Scholar 

  80. 80

    Silberstein, S. D. & Goadsby, P. J. Migraine: preventive treatment. Cephalalgia 22, 491–512 (2002).

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  81. 81

    Brandes, J. L. et al. Topiramate for migraine prevention: a randomized controlled trial. JAMA 291, 965–973 (2004).

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  82. 82

    Chronicle, E. & Mulleners, W. Anticonvulsant drugs for migraine prophylaxis. Cochrane Database Syst. Rev. 3, CD003226 (2004).

    Google Scholar 

  83. 83

    Diener, H.-C. et al. Topiramate in migraine prophylaxis — results from a placebo-controlled trial with propranolol as an active control. J. Neurol. 251, 943–950 (2004).

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  84. 84

    Silberstein, S. D., Neto, W., Schmitt, J., Jacobs, D. & MIGR-001 Study Group. Topiramate in migraine prevention: results of a large controlled trial. Arch. Neurol. 61, 490–495 (2004).

    Article  PubMed  PubMed Central  Google Scholar 

  85. 85

    Freitag, F. G. et al. A randomized trial of divalproex sodium extended-release tablets in migraine prophylaxis. Neurology 58, 1652–1659 (2002).

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  86. 86

    Klapper, J. Divalproex sodium in migraine prophylaxis: a dose-controlled study. Cephalalgia 17, 103–108 (1997).

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  87. 87

    Mathew, N. T. et al. Migraine prophylaxis with divalproex. Arch. Neurol. 52, 281–286 (1995).

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  88. 88

    Silvestrini, M. et al. Topiramate in the treatment of chronic migraine. Cephalalgia 23, 820–824 (2003).

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  89. 89

    Silberstein, S. D. et al. Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial. Headache 47, 170–180 (2007).

    Article  PubMed  PubMed Central  Google Scholar 

  90. 90

    Silberstein, S. et al. Topiramate treatment of chronic migraine: a randomized, placebo-controlled trial of quality of life and other efficacy measures. Headache 49, 1153–1162 (2009).

    Article  PubMed  PubMed Central  Google Scholar 

  91. 91

    Dodick, D. W. et al. The impact of topiramate on health-related quality of life indicators in chronic migraine. Headache 47, 1398–1408 (2007).

    Article  PubMed  PubMed Central  Google Scholar 

  92. 92

    Limmroth, V., Biondi, D., Pfeil, J. & Schwalen, S. Topiramate in patients with episodic migraine: reducing the risk for chronic forms of headache. Headache 47, 13–21 (2007).

    Article  PubMed  PubMed Central  Google Scholar 

  93. 93

    Mei, D. et al. Topiramate and triptans revert chronic migraine with medication overuse to episodic migraine. Clin. Neuropharmacol. 29, 269–275 (2006).

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  94. 94

    Lipton, R. B. et al. Topiramate intervention to prevent transformation of episodic migraine: the topiramate INTREPID study. Cephalalgia 31, 18–30 (2011).

    Article  PubMed  PubMed Central  Google Scholar 

  95. 95

    Pascual, J., Rivas, M. T. & Leira, R. Testing the combination beta-blocker plus topiramate in refractory migraine. Acta Neurol. Scand. 115, 81–83 (2007).

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  96. 96

    Silberstein, S. D. et al. Randomized, placebo-controlled trial of propranolol added to topiramate in chronic migraine. Neurology 78, 976–984 (2012).

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  97. 97

    Stovner, L. J. et al. A comparative study of candesartan versus propranolol for migraine prophylaxis: a randomised, triple-blind, placebo-controlled, double cross-over study. Cephalalgia 34, 523–532 (2013).

    Article  PubMed  PubMed Central  Google Scholar 

  98. 98

    Magalhães, E., Menezes, C., Cardeal, M. & Melo, A. Botulinum toxin type A versus amitriptyline for the treatment of chronic daily migraine. Clin. Neurol. Neurosurg. 112, 463–466 (2010).

    Article  PubMed  PubMed Central  Google Scholar 

  99. 99

    Yurekli, V. A. et al. The effect of sodium valproate on chronic daily headache and its subgroups. J. Headache Pain 9, 37–41 (2008).

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  100. 100

    Spira, P. J. & Beran, R. G. & Australian Gabapentin Chronic Daily Headache Group. Gabapentin in the prophylaxis of chronic daily headache: a randomized, placebo-controlled study. Neurology 61, 1753–1759 (2003).

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  101. 101

    Saper, J. R., Lake, A. E., Cantrell, D. T., Winner, P. K. & White, J. R. Chronic daily headache prophylaxis with tizanidine: a double-blind, placebo-controlled, multicenter outcome study. Headache 42, 470–482 (2002).

    Article  PubMed  PubMed Central  Google Scholar 

  102. 102

    Bigal, M., Rapoport, A., Sheftell, F., Tepper, D. & Tepper, S. Memantine in the preventive treatment of refractory migraine. Headache 48, 1337–1342 (2008).

    Article  PubMed  PubMed Central  Google Scholar 

  103. 103

    Calandre, E. P., Garcia-Leiva, J. M., Rico-Villademoros, F., Vilchez, J. S. & Rodriguez-Lopez, C. M. Pregabalin in the treatment of chronic migraine: an open-label study. Clin. Neuropharmacol. 33, 35–39 (2010).

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  104. 104

    Engel, E. R., Kudrow, D. & Rapoport, A. M. A prospective, open-label study of milnacipran in the prevention of headache in patients with episodic or chronic migraine. Neurol. Sci. 35, 429–435 (2014).

    Article  PubMed  PubMed Central  Google Scholar 

  105. 105

    Edvardsson, B. Atenolol in the prophylaxis of chronic migraine: a 3-month open-label study. SpringerPlus 2, 479 (2013).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  106. 106

    Pascual-Gómez, J. et al. Zonisamide in the preventive treatment of refractory migraine. Rev. Neurol. 50, 129–132 (in Spanish) (2010).

    PubMed  PubMed Central  Google Scholar 

  107. 107

    Volpe, F. M. An 8-week, open-label trial of duloxetine for comorbid major depressive disorder and chronic headache. J. Clin. Psychiatry 69, 1449–1454 (2008).

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  108. 108

    Ayata, C., Jin, H., Kudo, C., Dalkara, T. & Moskowitz, M. A. Suppression of cortical spreading depression in migraine prophylaxis. Ann. Neurol. 59, 652–661 (2006).

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  109. 109

    Bigal, M. E. et al. Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of chronic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study. Lancet Neurol. 14, 1091–1100 (2015).

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  110. 110

    Aurora, S. K. et al. OnabotulinumtoxinA for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program. Headache 51, 1358–1373 (2011).

    Article  Google Scholar 

  111. 111

    Lia, C., Tosi, P., Giardini, G., Caligiana, L. & Bottacchi, E. Onabotulinumtoxin A for prophylaxis in chronic migraine: preliminary data from Headache Regional Centre of Aosta Valley. Neurol. Sci. 35 (Suppl. 1), 175–176 (2014).

    Article  Google Scholar 

  112. 112

    Khalil, M., Zafar, H. W., Quarshie, V. & Ahmed, F. Prospective analysis of the use of OnabotulinumtoxinA (BOTOX) in the treatment of chronic migraine; real-life data in 254 patients from Hull, U. K. J. Headache Pain 15, 54 (2014).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  113. 113

    Grazzi, L. & Usai, S. Onabotulinum toxin A (Botox) for chronic migraine treatment: an Italian experience. Neurol. Sci. 36 (Suppl. 1), 33–35 (2015).

    Article  Google Scholar 

  114. 114

    Jackson, J. L., Kuriyama, A. & Hayashino, Y. Botulinum toxin A for prophylactic treatment of migraine and tension headaches in adults: a meta-analysis. JAMA 307, 1736–1745 (2012).

    CAS  Article  Google Scholar 

  115. 115

    Cady, R. K., Schreiber, C. P., Porter, J. A. H., Blumenfeld, A. M. & Farmer, K. U. A multi-center double-blind pilot comparison of onabotulinumtoxinA and topiramate for the prophylactic treatment of chronic migraine. Headache 51, 21–32 (2011).

    Article  Google Scholar 

  116. 116

    Silberstein, S. D. et al. OnabotulinumtoxinA for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients who had acute headache medication overuse at baseline. J. Neurol. Sci. 331, 48–56 (2013).

    CAS  Article  Google Scholar 

  117. 117

    Grazzi, L. & Usai, S. Botulinum toxin A: a new option for treatment of chronic migraine with medication overuse. Neurol. Sci. 35 (Suppl. 1), 37–39 (2014).

    Article  Google Scholar 

  118. 118

    Boudreau, G. P., Grosberg, B. M., McAllister, P. J., Lipton, R. B. & Buse, D. C. Prophylactic onabotulinumtoxinA in patients with chronic migraine and comorbid depression: an open-label, multicenter, pilot study of efficacy, safety and effect on headache-related disability, depression, and anxiety. Int. J. Gen. Med. 9, 79–86 (2015).

    Article  CAS  Google Scholar 

  119. 119

    Maasumi, K., Thompson, N. R., Kriegler, J. S. & Tepper, S. J. Effect of onabotulinumtoxinA injection on depression in chronic migraine. Headache 55, 1218–1224 (2015).

    Article  Google Scholar 

  120. 120

    Sandrini, G. et al. Botulinum toxin type-A in the prophylactic treatment of medication-overuse headache: a multicenter, double-blind, randomized, placebo-controlled, parallel group study. J. Headache Pain 12, 427–433 (2011).

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  121. 121

    Blumenfeld, A. M., Aurora, S. K., Laranjo, K. & Papapetropoulos, S. Unmet clinical needs in chronic migraine: rationale for study and design of COMPEL, an open-label, multicenter study of the long-term efficacy, safety, and tolerability of onabotulinumtoxinA for headache prophylaxis in adults with chronic migraine. BMC Neurol. 15, 100 (2015).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  122. 122

    Burstein, R., Zhang, X., Levy, D., Aoki, K. R. & Brin, M. F. Selective inhibition of meningeal nociceptors by botulinum neurotoxin type A: therapeutic implications for migraine and other pains. Cephalalgia 34, 853–869 (2014).

    Article  PubMed  PubMed Central  Google Scholar 

  123. 123

    Lackovic´, Z., Filipovic´, B., Matak, I. & Helyes, Z. Botulinum toxin type A activity in cranial dura: implications for treatment of migraine and other headaches. Br. J. Pharmacol. 173, 279–291 (2016).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  124. 124

    Cernuda-Morollón, E. et al. OnabotulinumtoxinA decreases interictal CGRP plasma levels in patients with chronic migraine. Pain 156, 820–824 (2015).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  125. 125

    Cady, R. et al. An exploratory study of salivary calcitonin gene-related peptide levels relative to acute interventions and preventative treatment with onabotulinumtoxinA in chronic migraine. Headache 54, 269–277 (2014).

    Article  PubMed  PubMed Central  Google Scholar 

  126. 126

    Hollanda, L., Monteiro, L. & Melo, A. Botulinum toxin type a for cephalic cutaneous allodynia in chronic migraine: a randomized, double-blinded, placebo-controlled trial. Neurol. Int. 6, 5133 (2014).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  127. 127

    Edvinsson, J., Warfvinge, K. & Edvinsson, L. Modulation of inflammatory mediators in the trigeminal ganglion by botulinum neurotoxin type A: an organ culture study. J. Headache Pain 16, 555 (2015).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  128. 128

    Sun-Edelstein, C. & Rapoport, A. M. Update on the pharmacological treatment of chronic migraine. Curr. Pain Headache Rep. 20, 6 (2016).

    Article  PubMed  PubMed Central  Google Scholar 

  129. 129

    Nestoriuc, Y. & Martin, A. Efficacy of biofeedback for migraine: a meta-analysis. Pain 128, 111–127 (2007).

    Article  PubMed  PubMed Central  Google Scholar 

  130. 130

    Busch, V. & Gaul, C. Exercise in migraine therapy — is there any evidence for efficacy? A critical review. Headache 48, 890–899 (2008).

    Article  PubMed  PubMed Central  Google Scholar 

  131. 131

    Irby, M. B. et al. Aerobic exercise for reducing migraine burden: mechanisms, markers, and models of change processes. Headache 56, 357–369 (2016).

    Article  Google Scholar 

  132. 132

    Harris, P., Loveman, E., Clegg, A., Easton, S. & Berry, N. Systematic review of cognitive behavioural therapy for the management of headaches and migraines in adults. Br. J. Pain 9, 213–224 (2015).

    Article  PubMed  PubMed Central  Google Scholar 

  133. 133

    Smitherman, T. A., Wells, R. E. & Ford, S. G. Emerging behavioral treatments for migraine. Curr. Pain Headache Rep. 19, 13 (2015).

    Article  Google Scholar 

  134. 134

    Luedtke, K., Allers, A., Schulte, L. H. & May, A. Efficacy of interventions used by physiotherapists for patients with headache and migraine-systematic review and meta-analysis. Cephalalgia 36, 474–492 (2016).

    Article  Google Scholar 

  135. 135

    Magis, D. & Schoenen, J. Advances and challenges in neurostimulation for headaches. Lancet Neurol. 11, 708–719 (2012).

    Article  Google Scholar 

  136. 136

    Saracco, M. G., Valfrè, W., Cavallini, M. & Aguggia, M. Greater occipital nerve block in chronic migraine. Neurol. Sci. 31 (Suppl. 1), S179–S180 (2010).

    Article  Google Scholar 

  137. 137

    Serra, G. & Marchioretto, F. Occipital nerve stimulation for chronic migraine: a randomized trial. Pain Physician 15, 245–253 (2012).

    Google Scholar 

  138. 138

    Silberstein, S. D. et al. Safety and efficacy of peripheral nerve stimulation of the occipital nerves for the management of chronic migraine: results from a randomized, multicenter, double-blinded, controlled study. Cephalalgia 32, 1165–1179 (2012).

    Article  Google Scholar 

  139. 139

    Schwedt, T. J., Dodick, D. W., Hentz, J., Trentman, T. L. & Zimmerman, R. S. Occipital nerve stimulation for chronic headache — long-term safety and efficacy. Cephalalgia 27, 153–157 (2007).

    CAS  Article  Google Scholar 

  140. 140

    Palmisani, S. et al. A six year retrospective review of occipital nerve stimulation practice — controversies and challenges of an emerging technique for treating refractory headache syndromes. J. Headache Pain 14, 67 (2013).

    Article  PubMed  PubMed Central  Google Scholar 

  141. 141

    Dodick, D. W. et al. Safety and efficacy of peripheral nerve stimulation of the occipital nerves for the management of chronic migraine: long-term results from a randomized, multicenter, double-blinded, controlled study. Cephalalgia 35, 344–358 (2015).

    Article  Google Scholar 

  142. 142

    Schoenen, J. et al. Migraine prevention with a supraorbital transcutaneous stimulator A randomized controlled trial. Neurology 80, 697–704 (2013).

    Article  Google Scholar 

  143. 143

    Hann, S. & Sharan, A. Dual occipital and supraorbital nerve stimulation for chronic migraine: a single-center experience, review of literature, and surgical considerations. Neurosurg. Focus 35, E9 (2013).

    Article  Google Scholar 

  144. 144

    Reed, K. L., Black, S. B., Banta, C. J. & Will, K. R. Combined occipital and supraorbital neurostimulation for the treatment of chronic migraine headaches: initial experience. Cephalalgia 30, 260–271 (2010).

    CAS  Article  Google Scholar 

  145. 145

    Straube, A., Ellrich, J., Eren, O., Blum, B. & Ruscheweyh, R. Treatment of chronic migraine with transcutaneous stimulation of the auricular branch of the vagal nerve (auricular t-VNS): a randomized, monocentric clinical trial. J. Headache Pain 16, 543 (2015).

    Article  Google Scholar 

  146. 146

    Kinfe, T. M. et al. Cervical non-invasive vagus nerve stimulation (nVNS) for preventive and acute treatment of episodic and chronic migraine and migraine-associated sleep disturbance: a prospective observational cohort study. J. Headache Pain 16, 101 (2015).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  147. 147

    Cecchini, A. P. et al. Vagus nerve stimulation in drug-resistant daily chronic migraine with depression: preliminary data. Neurol. Sci. 30, S101–S104 (2009).

    Article  Google Scholar 

  148. 148

    Mauskop, A. Vagus nerve stimulation relieves chronic refractory migraine and cluster headaches. Cephalalgia 25, 82–86 (2005).

    CAS  Article  Google Scholar 

  149. 149

    Hord, E. D., Evans, M. S., Mueed, S., Adamolekun, B. & Naritoku, D. K. The effect of vagus nerve stimulation on migraines. J. Pain 4, 530–534 (2003).

    Article  Google Scholar 

  150. 150

    Barbanti, P. et al. Non-invasive vagus nerve stimulation for acute treatment of high-frequency and chronic migraine: an open-label study. J. Headache Pain 16, 61 (2015).

    Article  PubMed  PubMed Central  Google Scholar 

  151. 151

    Lipton, R. B. et al. Single-pulse transcranial magnetic stimulation for acute treatment of migraine with aura: a randomised, double-blind, parallel-group, sham-controlled trial. Lancet Neurol. 9, 373–380 (2010).

    Article  Google Scholar 

  152. 152

    Bhola, R. et al. Single-pulse transcranial magnetic stimulation (sTMS) for the acute treatment of migraine: evaluation of outcome data for the UK post market pilot program. J. Headache Pain 16, 535 (2015).

    Article  Google Scholar 

  153. 153

    Antal, A., Kriener, N., Lang, N., Boros, K. & Paulus, W. Cathodal transcranial direct current stimulation of the visual cortex in the prophylactic treatment of migraine. Cephalalgia 31, 820–828 (2011).

    Article  PubMed  PubMed Central  Google Scholar 

  154. 154

    Dilli, E. et al. Occipital nerve block for the short-term preventive treatment of migraine: a randomized, double-blinded, placebo-controlled study. Cephalalgia 35, 959–968 (2015).

    Article  PubMed  PubMed Central  Google Scholar 

  155. 155

    Inan, L. E. et al. Greater occipital nerve blockade for the treatment of chronic migraine: a randomized, multicenter, double-blind, and placebo-controlled study. Acta Neurol. Scand. 132, 270–277 (2015).

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  156. 156

    Popeney, C. A. & Aló, K. M. Peripheral neurostimulation for the treatment of chronic, disabling transformed migraine. Headache 43, 369–375 (2003).

    Article  PubMed  PubMed Central  Google Scholar 

  157. 157

    Saper, J. R. et al. Occipital nerve stimulation for the treatment of intractable chronic migraine headache: ONSTIM feasibility study. Cephalalgia 31, 271–285 (2011).

    Article  PubMed  PubMed Central  Google Scholar 

  158. 158

    Lipton, R. B. et al. PRISM study: occipital nerve stimulation for treatment-refractory migraine [abstract]. Cephalalgia 29 (Suppl. 1), 30 (2009).

    Google Scholar 

  159. 159

    Chen, Y.-F. et al. Occipital nerve stimulation for chronic migraine — a systematic review and meta-analysis. PLoS ONE 10, e0116786 (2015).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  160. 160

    Chen, S.-P. et al. Vagus nerve stimulation inhibits cortical spreading depression. Pain 157, 797–805 (2016).

    Article  PubMed  PubMed Central  Google Scholar 

  161. 161

    Brighina, F. et al. rTMS of the prefrontal cortex in the treatment of chronic migraine: a pilot study. J. Neurol. Sci. 227, 67–71 (2004).

    Article  PubMed  PubMed Central  Google Scholar 

  162. 162

    Teepker, M. et al. Low-frequency rTMS of the vertex in the prophylactic treatment of migraine. Cephalalgia 30, 137–144 (2010).

    CAS  Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

The authors of this article were supported by the 7th Framework EU-project EuroHeadPain (#602633) and by the German Research Foundation, SFB936/A5 (to A.M).

Author information

Affiliations

Authors

Contributions

Both authors researched the data for the article, provided substantial contributions to discussions of its content, wrote the article and undertook review and/or editing of the manuscript before submission.

Corresponding author

Correspondence to Arne May.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Related links

FURTHER INFORMATION

IHS Classification ICHD-II

PowerPoint slides

Glossary

Cutaneous allodynia

In cutaneous allodynia, central sensitization to pain causes normally non-noxious tactile stimuli to skin (such as showering, shaving, brushing the hair or wearing tight clothing) to be experienced as painful.

Descending pain-modulating network

A top-down pain modulation system in which brain areas includingthe frontal lobe, hypothalamus and amygdala project on periaqueductal grey, which controls the transmission of nociceptive information in the spinal cord.

Biofeedback

Monitoring of bodily function and responses with biofeedback, such as electromyogram, can help relieve muscle tension and thereby alleviate headache.

Manual therapy

In patients with headache, manual therapy, also known as manipulative therapy — including massage therapy, physiotherapy and spinal manipulative therapy — aims to alleviate headache by relieving muscle tension and increasing mobility of the cervical spine.

Electrical stimulation

Therapeutic options using electrical current, voltage or induction of currents by magnetic fields to influence nerve or muscular functioning.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

May, A., Schulte, L. Chronic migraine: risk factors, mechanisms and treatment. Nat Rev Neurol 12, 455–464 (2016). https://doi.org/10.1038/nrneurol.2016.93

Download citation

Further reading